{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T15:43:43Z","timestamp":1773157423218,"version":"3.50.1"},"reference-count":13,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1111\/igc.0b013e3181daaf59","type":"journal-article","created":{"date-parts":[[2010,12,3]],"date-time":"2010-12-03T14:24:44Z","timestamp":1291386284000},"page":"772-780","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["Randomized Phase III Study of Canfosfamide in Combination With Pegylated Liposomal Doxorubicin Compared With Pegylated Liposomal Doxorubicin Alone in Platinum-Resistant Ovarian Cancer"],"prefix":"10.1016","volume":"20","clinical-trial-number":[{"clinical-trial-number":"nct00350948","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Ignace","family":"Vergote","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil J.","family":"Finkler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James B.","family":"Hall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ostap","family":"Melnyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert P.","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marsha","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James G.","family":"Keck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gail L.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elaine M.","family":"Rankin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James J.","family":"Burke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralph V.","family":"Boccia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolyn D.","family":"Runowicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter G.","family":"Rose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1111\/IGC.0b013e3181daaf59_bb0005","first-page":"225","article-title":"Cancer statistics, 2009","volume":"59","author":"Jemal","year":"2009","journal-title":"CA Cancer J Clin."},{"key":"10.1111\/IGC.0b013e3181daaf59_bb0010","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1136\/ijgc-00009577-200511001-00004","article-title":"Standard treatment in advanced ovarian cancer in 2005: the state of the art","volume":"15","author":"Bookman","year":"2005","journal-title":"Int J Gynecol Cancer."},{"key":"10.1111\/IGC.0b013e3181daaf59_bb0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ygyno.2004.07.011","article-title":"Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer","volume":"95","author":"Gordon","year":"2004","journal-title":"Gynecol Oncol."},{"key":"10.1111\/IGC.0b013e3181daaf59_bb0020","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1200\/JCO.2006.09.6735","article-title":"Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer","volume":"25","author":"Mutch","year":"2007","journal-title":"J Clin Oncol."},{"key":"10.1111\/IGC.0b013e3181daaf59_bb0025","series-title":"Structure and Function of Glutathione Transferases","first-page":"257","article-title":"Pharmaceutical targeting of GST isozymes","author":"Kauvar","year":"1993"},{"key":"10.1111\/IGC.0b013e3181daaf59_bb0030","doi-asserted-by":"crossref","first-page":"9328","DOI":"10.1073\/pnas.83.24.9328","article-title":"Similar biochemical changes associated with multidrug resistance in human breast cancer cells and carcinogen-induced resistance to xenobiotics in rats","volume":"83","author":"Cowan","year":"1986","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10.1111\/IGC.0b013e3181daaf59_bb0035","first-page":"388","article-title":"Characterization of a human squamous carcinoma cell line resistant to cis-diamminedichloroplatinum(II)","volume":"47","author":"Teicher","year":"1987","journal-title":"Cancer Res."},{"key":"10.1111\/IGC.0b013e3181daaf59_bb0040","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1093\/carcin\/9.7.1283","article-title":"Glutathione and glutathione-dependent enzymes in ovarian adenocarcinoma cell lines derived from a patient before and after the onset of drug resistance: intrinsic differences and cell cycle effects","volume":"9","author":"Lewis","year":"1988","journal-title":"Carcinogenesis."},{"key":"10.1111\/IGC.0b013e3181daaf59_bb0045","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1016\/j.ejca.2009.05.016","article-title":"Phase 3 randomized study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum refractory or resistant ovarian cancer","volume":"45","author":"Vergote","year":"2009","journal-title":"Eur J Cancer."},{"key":"10.1111\/IGC.0b013e3181daaf59_bb0050","first-page":"241","article-title":"Comparison of glutathione-S-transferase levels in predicting the efficacy of a novel alkylating agent","volume":"2","author":"Montali","year":"1995","journal-title":"Cell Pharmacol."},{"key":"10.1111\/IGC.0b013e3181daaf59_bb0055","series-title":"Cancer Chemotherapy and Biotherapy: Principles and Practice","first-page":"500","article-title":"Anthracyclines and anthracenediones","author":"Doroshow","year":"2001"},{"key":"10.1111\/IGC.0b013e3181daaf59_bb0060","doi-asserted-by":"crossref","unstructured":"Kavanagh JJ, Garcia A, Choi H, et al. Efficacy of TLK286 (TELCYTA) Alone and With Paraplatin or Doxil (Caelyx) in Platinum-Resistant Ovarian CancerVResults From 3 Phase 2 Studies. Proceedings of the Biennial International Gynecologic Cancer Society Meeting; October 3-7, 2004, Edinburgh, Scotland [Abstract no. 095].","DOI":"10.1136\/ijgc-00009577-200409001-00095"},{"key":"10.1111\/IGC.0b013e3181daaf59_bb0065","unstructured":"Xu H, Namgoong S-Y, Roth E, et al. Synergistic Effect of TELCYTA (TLK286) in Combination With Paclitaxel, Doxorubicin, Carboplatin, Oxaliplatin, Cisplatin, Docetaxel, Gemcitabine and Iressa in Human Cancer Cells. Proceedings of the Annual Meeting of the American Association for Cancer Research; March 27-31, 2004, Orlando, FL [Abstract no. 2008]."}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2FIGC.0b013e3181daaf59","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24036624?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24036624?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1111\/IGC.0b013e3181daaf59","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T01:17:55Z","timestamp":1753233475000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24036624"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":13,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["S1048891X24036624"],"URL":"https:\/\/doi.org\/10.1111\/igc.0b013e3181daaf59","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2010,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Randomized Phase III Study of Canfosfamide in Combination With Pegylated Liposomal Doxorubicin Compared With Pegylated Liposomal Doxorubicin Alone in Platinum-Resistant Ovarian Cancer","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/IGC.0b013e3181daaf59","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 by IGCS and ESGO","name":"copyright","label":"Copyright"}]}}